FINANCIAL HIGHLIGHTS RMB’000 (Unaudited)Six Months Ended June 30Three Months Ended June 302025202420252024 Revenue4,645,407 4,610,641 2,307,412 2,473,766 - Office software and services2,657,122 2,413,079 1,355,653 1,187,730 - Online games and others1,988,285 2,197,562 951,759 1,286,036 Gross Profit3,772,214 3,782,688 1,853,628 2,042,035 Operating Profit984,111 1,395,615 382,658 794,037 Profit Attributable to Owners of the Parent816,314 677,923 532,440 393,353 Basic Earnings Per Share (RMB)0.60 0.51 0.39 0.29 HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its unaudited 2025 interim results and its second quarter results for the period ended 30 June 2025.For the first half of 2025, the revenue of Kingsoft increased by 1% year-on-year to RMB 4,645.4 million. Revenue from the office software and services represented 57% and online games and others represented 43% of total revenue. Gross profit reached RMB 3,772.2 million.For the second quarter of 2025, the Company’s revenue reached RMB 2,307.4 million. Revenue from office software and services and online games and others represented 59% and 41%, respectively, of total revenue for the second quarter of 2025. Gross profit for the second quarter of 2025 was RMB 1,853.6 million.Mr. Jun LEI, Chairman of the Company, commented: “In the second quarter, we advanced core businesses steadily in line with established strategy and firmly positioned for the future. Kingsoft Office focused on ‘AI, collaboration, and internationalization’, continued to strengthen the allocation of R&D resources in related fields, and developed solutions deeply aligned with user scenario needs to sustain competitiveness in the field of intelligent office. The online games business continued advancing content innovation and global expansion, achieving the development of flagship IPs and new game genres.”Mr. Tao ZOU, Chief Executive Officer of the Company, added: “The total revenue for the second quarter amounted to RMB 2,307.4 million, representing a year-on-year decrease of 7%, among which the revenue from the office software and services business was RMB 1,355.7 million, representing a year-on-year increase of 14%. Revenue from the online games and others business was RMB 951.8 million, representing a year-on-year decrease of 26%, primarily due to the high base in the same period last year.”BUSINESS REVIEWOffice Software and ServicesFor the first half of 2025, revenue from the office software and services business increased by 10% year-on-year to RMB 2,657.1 million. The increase was mainly attributable to the growth of WPS individual and WPS 365 businesses of Kingsoft Office. Revenue in the second quarter increased by14% year-on-year to RMB 1,355.7 million.In the second quarter, the office software and services business continued its healthy development. For WPS AI, Kingsoft Office released WPS AI 3.0 and launched the native Office intelligent agent ‘WPS Lingxi’ — the core capability module of WPS AI 3.0. WPS AI 3.0 drove deep integration between AI and office software through bidirectional transformation, achieving native embedding of AI capabilities and deep involvement in office workflows. WPS Lingxi integrated multiple AI functions, marking the transition from tool-based AI applications to collaborative intelligent agents. We also implemented intelligent upgrades to WPS 365 components, and launched messaging, meeting, and email assistants to boost office efficiency.For WPS individual business, Kingsoft Office expanded AI benefits and rolled out new AI products. In overseas markets, we initiated the development of the new WPS International Edition to gradually migrate domestic high-value features. For WPS 365 business, we continuously deepened penetration into industries and scenarios, actively promoted the implementation of AI projects, and engaged in co-creation with key clients to replicate and scale up typical solutions. For WPS software business, we actively participated in the bidding for domestic office software of central and local governments and enterprises. Our products maintained a leading share in both flow layout and fixed layout document software market.Online Games and othersFor the first half of 2025, revenue from online games and others business reached RMB 1,988.3 million, and revenue for the second quarter of 2025 was RMB 951.8 million. In the second quarter, the online games business continued to enrich the brand value of classic JX series and expand into new game genres.During the second quarter, JX3 Online, the flagship IP, maintained engaged player base through consistent content updates and technical optimization. The Fate of Sword: Zero was launched, building upon the core gameplay of the classic JX series IP while introducing innovative explorations. The anime shooter game Snowbreak: Containment Zone sustained its long-term operation, keeping stable user base. The self-developed sci-fi mech game Mecha BREAK commenced its global public beta in July. On its launch day, it topped Steam’s lists for both “Most Played” and “Trending Games,” and earned high scores from several international authoritative gaming outlets like IGN.Additionally, we actively strengthened our collaboration with high-quality overseas IPs, deepening the localized operational capabilities in domestic market. The social deduction game Goose Goose Duck obtained the license approval in June and was expected to launch in the second half of the year. The number of pre-registrations exceeded 5 million, demonstrating its popularity. Cats & Soup: Magic Recipe, the sequel to Cats & Soup, secured its license in May. For the latter half of the year, we will focus on refining the operations of our core titles and continuously optimizing the gaming experience based on players’ feedback.Mr. Jun LEI concluded, “In the coming quarters, Kingsoft Office will continue to increase its R&D investments in AI and collaboration, and promote the implementation of its products and services across a wider range of office scenarios in various industries. The online games business will remain focused on premium games, continue to cultivate its IP franchise, steadily advance its global expansion and achieve long-term operations. We believe that these efforts will strengthen the Group’s core competitiveness and lay a solid foundation to achieve long-term high-quality growth.”About Kingsoft Corporation LimitedKingsoft (3888.HK) is a leading Chinese software and internet service company listed on the Hong Kong Stock Exchange. It has three main subsidiaries: Kingsoft Office, Seasun Holdings and Kingsoft Shiyou. With the implementation of the “transformation toward mobile internet” strategy, Kingsoft has completed a comprehensive transformation in its overall business and management model. The Company has established a strategic layout with office software and interactive entertainment as its pillars, and cloud services and artificial intelligence as its new starting points. Kingsoft has more than 8,000 employees worldwide and holds a significant market share domestically. For more details, please refer to http://www.kingsoft.com.Kingsoft Investor Relations:Li Yinan Tel: (86) 10 6292 7777Email: ir@kingsoft.comFor further queries, please contact Hill and Knowlton:Ovina Zhu Tel: (852) 2894 6315Email: kingsofthk@hkstrategies.com Copyright 2025 ACN Newswire via SeaPRwire.com.

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com.

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the artificial intelligence (AI) sector emerged as one of the most prominent structural investment themes in capital markets, sparking significant market enthusiasm. The market capitalization of leading companies in multiple AI-related segments saw significant increases, and the overall sector valuation rose markedly. As a result, the AI sector has become a high-prosperity track favored by institutional investors for portfolio allocation.Market analysts expect AI applications to emerge as a breakout sector as artificial intelligence deepens its integration across industries. Companies demonstrating both product innovation and real-world deployment capability are likely to draw heightened investor appetite. Among them, Qunabox Group (00917.HK), with its forward-looking strategic layout in “AI + Consumption Scenarios,” along with sustained high-intensity investment in technology and strong product commercialization capabilities, is poised to stand out in this wave of technology-scenario integration, potentially establishing itself as one of the most promising growth companies in this sector.On August 15, Qunabox Group released its 2025 interim results. In the first half of 2025, the Company achieved robust growth driven by continuous advancements in business model innovation, service capabilities enhancement, industry reputation building, and improved team execution. Leveraging its competitive advantages accumulated through years of sustained investment in AI, Qunabox Group seized the policy-driven opportunities in AI and consumption industries. The Company achieved revenue of RMB676.2 million, representing a year-on-year increase of 31.3%, while gross profit rose to RMB385.5 million, up 37.0% year-on-year, maintaining strong growth momentum and solidifying the Company’s leading position in China’s AI interactive marketing industry.Strategic Upgrade: Comprehensive Industrial Expansion from AI+ Marketing to AI+ Consumption ScenariosIn response to the profound transformation brought by the AI industrial revolution, Qunabox Group has fully upgraded its core strategy to focus on “AI + Consumption Scenarios”. The Company is concentrating on two key application scenarios – AI+ Marketing and AI+ Entertainment – while accelerating innovation in AI-powered services and product development. To support this strategic shift, the Company significantly increased its research and development investment in the first half of 2025 to RMB77.8 million, representing a year-on-year growth of 107.7%. As of 30 June 2025, Qunabox Group has established a robust technological moat, with cumulative registrations of 159 software copyrights and 34 patent applications.In terms of technology research and development, Qunabox Group has built an AI technology middle platform that reinforces its foundational technical architecture. By innovatively adopting a modular design approach, the Company has developed a reusable AI capabilities pool, significantly enhancing research and development efficiency and strengthening the scalability of its technologies across diverse application scenarios. Meanwhile, its self-developed multi-modal neural integrated collaborative engine—the AI-OMNI Engine (AI-Orchestrated Multimodal Neural Integration) —has achieved key technological breakthroughs, successfully empowering the three core layers of “perception, decision, execution,” significantly enhancing edge intelligence and multi-scenario adaptability.Notably, Qunabox Group has also made forward-looking advancements in the field of AI Agent. According to the Company’s 2025 interim report, it has deeply integrated AI Agent technology with its self-developed terminal operation and maintenance (O&M) large model, establishing a more intelligent O&M management system. This technological integration not only enables intelligent task dispatching and automated maintenance guidance, but also drives the transformation of O&M models from traditional “reactive maintenance” to “proactive prevention.” Industry analysts believe this move significantly enhances the professional capabilities and execution efficiency of terminal operation teams, marking a critical step in Qunabox Group’s journey toward operational intelligence. Moreover, it provides solid operational support for the large-scale implementation of the company’s “AI + Consumer Scenarios” strategy.Rapid Unleashing of the “AI+ Marketing” Business Flywheel EffectIn terms of marketing business, Qunabox Group has built a high-growth business flywheel by continuously driving the coordinated evolution of five core elements including product, client, data, technology and operations. In the first half of 2025, Qunabox Group’s marketing service revenue reached RMB568.0 million, representing a year-on-year increase of 37.9%; gross profit was RMB353.3 million, up 43.8% year on year. Among these, revenue from the standardized marketing services segment increased by 34.3% year on year, while revenue from the high-margin value-added marketing services segment grew by 63.1%, effectively boosting the Company’s overall profitability.On the one hand, while maintaining strong and stable partnerships with brand customers, Qunabox Group further tapped into the potential of KA customers by expanding service application scenarios, enriching and optimizing AI interactive marketing products, developing data strategy products, and refining its marketing product portfolio and service pattern, thereby broadening its collaboration with major customers. Leveraging its proprietary AI-OMNI Multi-modal Neural Synergy Engine, the Company has achieved dual breakthroughs in AI digital shopping assistants—enhancing both intelligent interaction capabilities and visual expressiveness—thereby significantly boosting customer engagement and conversion rates at offline terminals. In the first half of 2025, the average revenue per KA customer increased to RMB16.2 million, representing a year-on-year growth of 52.2%, providing strong support for high-quality revenue growth. On the other hand, by leveraging its technological and operational capabilities to advance the modularization of its marketing system, the Company enhanced its flexible combination capabilities between standardized marketing services and value-added marketing service modules, enabling complementary synergy, flexible integration, and efficient reuse between standardized and value-added services.It can be said that Qunabox Group’s “AI + Marketing” strategy has evolved from technological leadership to systematic growth, forging a five-dimensional moat integrating products, clients, data, technology, and operations—laying a robust foundation for sustained future growth.“AI+ Entertainment” Goes Global: Middle East Expansion Marks the Start of Ambitious Worldwide GrowthIn addition to marketing scenarios, Qunabox Group is actively capitalizing on the emerging “emotional consumption” trend in expanding the boundaries of AI entertainment applications. The Company has strategically positioned “AI + Entertainment” as a new frontier, aiming to build world-leading AI-powered indoor entertainment spaces, with the Middle East market as its first stop for global expansion. In the first half of 2025, Qunabox Group established an Overseas Entertainment Division, focusing on the strategic planning, product design, and commercialization of AI indoor entertainment spaces, to further strengthen the execution efficiency and market expansion of this business.Currently, the Division has completed its organizational structure and preparation for the first batch of venues, successfully obtaining the relevant local licenses. At the same time, core tasks such as product design and optimization, software and hardware system development, and the construction of content ecosystems are steadily progressing. Industry experts suggest this move may represent a strategic play in Qunabox Group’s global “IP incubation” initiative. By leveraging AI-generated technology and deep user behavior insights, the Company could develop original virtual characters and interactive experiences that balance local cultural relevance with global appeal. Through cross-media storytelling and digital asset management, these efforts may cultivate high-value original IPs. Such IPs are expected to serve as the core driver for AI entertainment spaces while extending into diverse monetization scenarios—including digital merchandise, brand collaborations, and fan engagement—significantly enhancing both user retention and commercial potential.In addition, Qunabox Group will deepen its diversification layout around the “AI + Consumption Scenarios” strategy. Through strategic acquisitions and ecosystem synergies, the Company will systematically extend its business boundaries and value chain depth to achieve high-quality, scalable growth.From a medium-to-long-term perspective, AI will continue to be the core driving force of industrial transformation, accelerating its penetration into marketing, entertainment, retail, and other scenarios. As a leading company in AI consumption scenarios, Qunabox Group remains at the forefront of AI industry applications through continuous strategic upgrades, technological innovation, and product implementation, building a long-term, sustainable, and high-quality growth flywheel. With the ongoing advancement of its “AI + Consumption Scenarios” strategy, Qunabox Group will unlock new frontiers for innovative growth. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

Development Highlights- During the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.- As of 30 June 2025, the Group had a total of 37 innovative drug candidates in the field of oncology, 7 innovative drug candidates related to liver/metabolic diseases, 13 innovative drug candidates related to the respiratory, and 6 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 2 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 11 innovative oncology drug candidates, 1 innovative liver/metabolic diseases drug candidate, 3 innovative respiratory system drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. In addition, the Group had a total of 13 biosimilar or generic drug oncology candidates, 6 additional biosimilar or generic liver/metabolic diseases drug candidates, 12 biosimilar or generic respiratory system drug candidates, and 6 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. It has been approved for nine indications, and three other indications are currently in the marketing application stage. In addition, Anlotinib has a number of new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2024, the Group obtained approval for and launched a total of five national category 1 innovative oncology drugs, namely, Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets). It also obtained approval for and launched 4 oncology biosimilars, including Anbesi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab Injection), and Paletan (Pertuzumab Injection). The sales volume of these products accelerated rapidly in the first half of 2025, and they have become important contributors to the Group’s revenue growth.- Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and enrollment of the patients in the global main cohort has been completed. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national VBP. The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP.- Zepolas/Debaian (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. By upgrading the dosage form, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2025 (the “Period”).During the Period, the Group recorded revenue of approximately RMB17.57 billion, a year-on-year increase of approximately 10.7%. Profit attributable to owners of the parent from continuing operations as reported was approximately RMB3.39 billion, a year-on-year increase of approximately 140.2%. Earnings per share attributable to owners of the parent were approximately RMB18.82 cents. The significant year-over-year increase in profit attributable to owners of the parent from continuing operations was mainly driven by the notable growth in revenue and significant increase in dividend income and fair value gain on investments during the Period. Underlying profit attributable to owners of the parent (non-HKFRSs measure) was approximately RMB3.09 billion, a YOY increase of approximately 101.1%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB11.1 billion, bank deposits classified as non-current assets of approximately RMB10.1 billion, and wealth management products of approximately RMB9.29 billion in total, and total fund reserves amounting to approximately RMB30.49 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK5 cents per share (1H2024: HK3 cents).Sales: Strong momentum in R&D innovation with volume growth across multiple fieldsAlways placing utmost importance on research and development (“R&D”), the Group has consistently increased investments to enhance R&D quality and efficiency, which has led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. During the Period, sales of oncology drugs increased by 24.9% year-on-year to approximately RMB6.69 billion, accounting for approximately 38.1% of the Group's revenue. Sales of surgical/analgesic medications increased by 20.2% year-on-year to approximately RMB3.11 billion, accounting for approximately 17.7% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. The EGFR/cMet bispecific antibody TQB2922 is about to initiate a Phase III clinical trial for second-line NSCLC, while the EGFR/cMet bispecific antibody ADC TQB6411 is currently enrolling patients for its Phase I trial, with both products progressing at the forefront in China. Also, the Group is deeply invested in the three major subtypes of breast cancer. The CDK2/4/6 inhibitor “Culmerciclib Capsule (TQB3616)” has the potential to become a best-in-class (BIC) therapy for HR+/HER2- breast cancer. The HER2 bispecific ADC TQB2102 demonstrates potentially superior safety compared to DS-8201, with multiple indications being explored simultaneously, including three breast cancer Phase III trials advancing rapidly. Additionally, the Group has systematically targeted key gastrointestinal cancers such as colorectal, gastric, pancreatic, and liver cancers. LM-108 (CCR8 monoclonal antibody) and TQB2868 (PD-1/TGF-β bifunctional fusion protein) are progressing at the fastest pace globally, with current clinical data showing significant potential.In the field of surgery/analgesia, the Group continuously focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. During the Period, the Group drove the sustained rapid sales growth of Zepolas, and the second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. Meanwhile, Putanning, which was approved in May 2025, is expected to become a new growth driver in this field due to its strengths, such as long-acting analgesia and excellent safety.R&D: Fully Committed to Advancing Innovative Product Development with Enhanced R&D InvestmentDuring the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.The Group has always placed the utmost importance on R&D, continuously improving its R&D capabilities and speed. It considers R&D the foundation for its sustainable development and has continuously increased its investment in R&D. For the six months ended 30 June 2025, R&D costs amounted to approximately RMB3,187.56 million, representing approximately 18.1% of the Group’s revenue. Including capitalised R&D expenditure, approximately 95.7% was recognised in the statement of profit or loss.Prospect: Deepening Innovation and Global Expansion to Accelerate the Building of Global Pharmaceutical Innovation CompetitivenessChina’s pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country’s biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the “passive mover” towards the “paralleled player,” or even the “market leader” on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognized and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas – oncology, liver/metabolic diseases, respiratory diseases, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. In the meantime, the Group is vigorously promoting its global strategic collaboration deployments through diversified approaches of collaborations such as business development (BD), strategic acquisitions, etc. In July 2025, the Group announced the full acquisition of LaNova Medicines. LaNova Medicines boasts world-leading antibody discovery and ADC technology platforms, including the Tumor Microenvironment Specific Antibody Development Platform (LM-TME™), the Targeted Antibody Discovery Platform (LM-Abs™), the New Generation ADC Platform (LM-ADC™), and the T-cell Engager Platform (LM-TCE™). The acquisition will further enhance the Group's innovative R&D capabilities and accelerate the growth of the Group's innovative business. In addition, the LaNova Medicines’ outstanding and efficient R&D team will join the Group to further strengthen its innovation and R&D talent pool, ensuring the sustained delivery of high-quality innovation outcomes, and supporting the long term development of the Group’s innovation ecosystem.Looking ahead, the Group will remain focused on innovation, while enhancing R&D efficiency and quality across its four major therapeutic areas. The Group will also accelerate its progress of internationalization, thereby striving for rapid business expansion alongside steady performance improvement.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver/Metabolic Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for seven consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.